Teva Pharmaceutical Industries Ltd ADR diskutieren
Teva Pharmaceutical Industries Ltd ADR
WKN: 883035 / Symbol: TEVA / Name: Teva Pharma / Aktie / Pharmazeutika / Large Cap /
25,00 €
2,46 %
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Barclays PLC from $20.00 to $21.00. They now have an "overweight" rating on the stock.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Jefferies Financial Group Inc. from $19.00 to $23.00. They now have a "buy" rating on the stock.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) was upgraded by analysts at Argus from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at UBS Group AG from $22.00 to $24.00. They now have a "buy" rating on the stock.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Barclays PLC from $21.00 to $22.00. They now have an "overweight" rating on the stock.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at UBS Group AG from $24.00 to $26.00. They now have a "buy" rating on the stock.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Barclays PLC from $22.00 to $25.00. They now have an "overweight" rating on the stock.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Barclays PLC from $25.00 to $28.00. They now have an "overweight" rating on the stock.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Piper Sandler from $23.00 to $30.00. They now have an "overweight" rating on the stock.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at UBS Group AG from $28.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target lowered by analysts at Barclays PLC from $28.00 to $26.00. They now have an "overweight" rating on the stock.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target lowered by analysts at Bank of America Co. from $23.00 to $20.00. They now have a "buy" rating on the stock.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Bank of America Co. from $20.00 to $22.00. They now have a "buy" rating on the stock.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $23.00 price target on the stock, up previously from $21.00.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $25.00 price target on the stock.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $24.00 price target on the stock.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) had its price target lowered by analysts at UBS Group AG from $24.00 to $23.00. They now have a "buy" rating on the stock.
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at UBS Group AG from $23.00 to $26.00. They now have a "buy" rating on the stock.
Ratings data for TEVA provided by MarketBeat
Neueste Beiträge
Barclays_PLC in Elanco Animal Health Inc. diskutieren